source
- Lilly reports 79% response rate for FRα-directed ADC in platinum-sensitive ovarian cancerLilly presented phase 1 data on its FRα‑directed antibody‑drug conjugate, sofetabart mipitecan (Sofe-M), combined with bevacizumab in patients whose ovarian cancer had progressed after platinum the…
- Eli Lilly teams with Hong Kong's Metis TechBio in up to $1.1 billion AI nanoparticle partnershipEli Lilly has entered a partnership with Hong Kong‑based Metis TechBio to access an artificial‑intelligence driven platform for designing lipid nanoparticles that can improve drug delivery. The co…